New Standards of Care in the Management of Prostate Cancer - Episode 5
Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the treatment of prostate cancer with androgen deprivation therapy (ADT) and note that additional research is necessary to help determine which patient populations are at highest risk for developing resistance following ADT.
Dr Klein explains that after a patient receives ADT, the only indicator that providers have for detecting resistance is disease progression. Unfortunately, he adds, each patient responds differently and the time to onset of resistance is variable.
For this reason, Dr Klein emphasizes the need for additional population-based clinical studies and research on the activation of signaling pathways. Being able to categorize patients, look at specific cell surface markers, and conduct additional next-generation sequencing can help providers appropriately manage their patients, he remarks.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs